First-Line Sugemalimab plus Chemotherapy for Advanced Gastric Cancer

In this randomized clinical trial of 479 patients with programmed death-ligand 1 combined positive score of 5 or more, sugemalimab plus chemotherapy significantly prolonged overall survival and progression-free survival compared with chemotherapy alone, with a manageable safety profile.